Registry for prostate cancer on active surveillance
Part of Cancer, Kidney & urinary clinical trials.
This study follows men with low-risk prostate cancer who choose active surveillance (watching closely instead of immediate treatment). It aims to better track which monitoring results stay reassuring over time, and when treatment might be needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man under 80 years old
- Your prostate cancer was confirmed on biopsy (at least 10 biopsy samples taken)
- Your PSA blood test before biopsy is 10 or less
- Your PSA density is less than 0.15
- Your cancer is low stage (T1 to T2a) and the biopsy Gleason score is 6 or less
- You have low-risk MRI and limited cancer spread in the biopsy (no PIRADS 5; at most 2 positive cores; no more than 20% involvement in any one core)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a registry study that follows men with low-risk prostate cancer who choose active surveillance instead of immediate treatment. It helps doctors understand how safe and effective active surveillance is, including confirming results with repeat biopsies.
This trial studies a “watchful waiting” approach, where doctors closely monitor certain prostate cancers with regular checkups and repeat biopsies. It may help people avoid or delay treatment side effects while watching for signs the cancer needs treatment.
This trial follows men with prostate cancer who choose “active surveillance” instead of immediate treatment. It tests whether careful tracking (including patient reports) can help manage cancer over time and guide decision-making.
This trial studies whether men with low-risk prostate cancer can safely avoid treatment by closely monitoring their cancer over many years. It tests a new approach to see if it is better than the current standard of care.
This study checks whether people with a low chance of prostate cancer can be monitored closely without having an immediate prostate biopsy. It uses PSA blood tests and prostate MRI to sort who may safely wait.
This study tests whether watching low-risk prostate cancer closely (instead of treating right away) is safe. It may help some people avoid early treatments and their side effects while still keeping a close eye on the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.